Revised guidelines for Coronavirus disease 19 management in hematopoietic cell transplantation and cellular therapy recipients (August 2022) Guidelines

   


Authors: Dioverti, V.; Boghdadly, Z. E.; Shahid, Z.; Waghmare, A.; Abidi, M. Z.; Pergam, S.; Boeckh, M.; Dadwal, S.; Kamboj, M.; Seo, S.; Chemaly, R. F.; Papanicolaou, G. A.
Title: Revised guidelines for Coronavirus disease 19 management in hematopoietic cell transplantation and cellular therapy recipients (August 2022)
Abstract: This document is intended as a guide for diagnosis and management of Coronavirus Disease 2019 (COVID-19), caused by the virus SARS-CoV-2, in adult and pediatric HCT and cellular therapy patients. This document was prepared using available data and with expert opinion provided by members of the (ASTCT) Infectious Diseases Special Interest Group (ID-SIG) and is an update of pervious publication. Since our original publication in 2020, the NIH and IDSA have published extensive guidelines for management of COVID-19 which are readily accessible ( NIH Guidelines, IDSA Guidelines ). This update focuses primarily on issues pertaining specifically to HCT/cellular therapy recipients. Information provided in this manuscript may change as new information becomes available. © 2022 The American Society for Transplantation and Cellular Therapy
Keywords: adult; child; nonhuman; immunoglobulin; practice guideline; hematopoietic stem cell transplantation; monoclonal antibody; donor; immunotherapy; cell therapy; virus infection; immunomodulating agent; infection prevention; biological therapy; corticosteroid; mycosis; therapy; opportunistic infection; antiviral therapy; antiinflammatory agent; hematopoietic cell transplantation; randomized controlled trial (topic); unrelated donor; passive immunization; combination drug therapy; antibody therapy; cellular therapy; pre-exposure prophylaxis; humans; human; article; cell- and tissue-based therapy; related donor; coronavirus disease 2019; covid-19; sars-cov-2; remdesivir; sars-cov-2 convalescent plasma; sars-cov-2 vaccine; molnupiravir; nirmatrelvir plus ritonavir
Journal Title: Transplantation and Cellular Therapy
Volume: 28
Issue: 12
ISSN: 2666-6375
Publisher: Elsevier Inc.  
Date Published: 2022-12-01
Start Page: 810
End Page: 821
Language: English
DOI: 10.1016/j.jtct.2022.09.002
PUBMED: 36103987
PROVIDER: scopus
PMCID: PMC9464362
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85140787630&doi=10.1016%2fj.jtct.2022.09.002&partnerID=40&md5=cb8181bd04b42d6efd07d935ff7bb3fa
Notes: Article -- Export Date: 3 January 2023 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Susan Seo
    120 Seo
  2. Genovefa A Papanicolaou
    238 Papanicolaou
  3. Mini Kamboj
    158 Kamboj
  4. Zainab Shahid
    19 Shahid
Related MSK Work